LPA-HM0P111-100μg / 询价
LPA-HM0P111-100μgx5 / 询价
LPA-HM0P111-100μgx10 / 询价
- 关联产品
- 客服电话
- 技术支持
Human LPAR1/LPA receptor 1 VLP
Recombinant Human LPAR1/LPA receptor 1 VLP is expressed from HEK293.It contains Met1-Val364 (It may have cross reaction with anti-His antibody) [Accession | Q92633-1].
The target protein has a predicted MW of 43.1 kDa.
> 90% as determined by HPLC
Less than 1 EU per μg by the LAL method.
Supplied as 0.22μm filtered solution in PBS, 150mM L-Arginine (pH 7.4). Notice: If you need it for immunization, water-soluble adjuvant is recommended.
Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
The purity of Human LPAR1 VLP is greater than 90% as determined by SEC-HPLC.
Immobilized Human LPAR1 VLP at 5μg/ml (100μl/well) on the plate. Dose response curve for Anti-LPAR1 Antibody, hFc Tag with the EC50 of 20.4ng/ml determined by ELISA (QC Test).
Lysophosphatidic acid receptor 1 (LPAR1) is one of the G protein-coupled receptors and binds with lysophosphatidic acid (LPA). It is involved in diverse biological functions, including chemotaxis, proliferation, cell differentiation, platelet aggregation, and tumor progression. A set of papers indicated that LPAR1 is a prognostic biomarker in various cancers and takes an important part in the development of prostate cancer.
LPA receptor 1; LPA-1; EDG2; LPA1; EDG-2; GPCR26; GPR26; LPAR1
Shi J, Jiang D, Yang S, Zhang X, Wang J, Liu Y, Sun Y, Lu Y, Yang K. LPAR1, Correlated With Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer. Front Oncol. 2020 Jun 10;10:846. doi: 10.3389/fonc.2020.00846. PMID: 32656075; PMCID: PMC7325998.
